LH symptoms are highly variable (as will be the subjects in age, gender, race, comorbidities, etc.) and in simple terms the more variable the data the more observations are required to show statistical significance. This is a small trial even for a phase two trial. A few more participants would not cost much more, would have been easy to recruit and could be very useful in terms of making sure the results aren’t ambiguous. In general more data is always better. I hope these guys aren’t being penny wise and pound foolish.